Bristol-Myers Squibb

Urology FDA approvals of 2016Urology-related FDA approvals from 2016 encompassed drugs and devices for prostate cancer, renal cell carcinoma, bladder cancer, stone disease, and more.
Risks associated with omega-3 supplementation
Risks associated with omega-3 supplementationDuring my preoperative visit, my surgeon handed me a list of no less then 165 medications and supplements that I should stop taking 14 days prior to my surgery. Fish and krill oil were on the list, as were aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs)—as expected.
Uro Pipeline: Data from mUC combination therapy suggests efficacy, safetyOther pipeline developments discussed include a bladder cancer test, a male infertility assay, and the first oral dosage treatment for hypogonadism.
Merck value rises after new Keytruda approvalMerck’s Wall Street value is climbing after its cancer drug pembrolizumab (Keytruda) received yet another approval from FDA.
New agreement supports value-based pharma contractingIndustry experts are using their proprietary data/analysis to help structure contracts between pharmaceutical companies and plans.
Opdivo snags two new cancer approvalsNivolumab (Opdivo, Bristol-Myers Squibb) received two new approvals from FDA to treat two different cancers.
New diagnostic tests help physicians predict HCV drug resistanceHep C virus testing supports value of diagnostics in precision medicine.
Study: Shorter hospital stays with XareltoUS hospitals using rivaroxaban (Xarelto, Janssen Pharmaceuticals) instead of warfarin (Coumadin, Bristol-Myers Squibb) to treat patients diagnosed with a venous thromboembolism (VTE) may save nearly $2,000 per patient and shorten a patient’s hospital stay by approximately 1.5 days, according to a new study.
FDA expands Opdivo use for metastatic melanomaFDA has approved Bristol-Myers Squibb’s Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the treatment of patients with metastatic melanoma.
FDA approves a new immune-stimulating drug to treat multiple myelomaFDA has approved elotuzumab (Empliciti, Bristol-Myers Squibb and AbbVie) for the treatment of multiple myeloma.